A bispecific targeting TRAIL-R2 and CD3 enabled the interaction of T cells with TRAIL-R2+ triple-negative breast cancer cells, an aggressive malignancy with poor prognosis [90]. Here, TNFRSF10B is linked to triple-negative breast carcinoma.